A harmless pharmaceutical for psoriasis may not be so harmless.

[Guest guest]



Search Results for Google

Print this Release

November 27, 2007 07:00 AM Eastern Time

Provectus Pharmaceuticals, Inc. Phase 2 Clinical Trial Opens for Psoriasis Patients

First Patient Treated with Topical PH-10 at Mount Sinai School of Medicine

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:PVCT, http://www.pvct.com) has begun recruiting patients for the Phase 2 clinical trial of topical PH-10 for the treatment of psoriasis, and has commenced treatment of the first patient.

The psoriasis study is designed to evaluate efficacy of topically applied PH-10 in a total of twenty-five subjects. In the study, PH-10 will be topically applied twice weekly for up to twelve weeks. Response will be observed for sixteen weeks. The study is being conducted at the Mount Sinai School of Medicine in New York and is expected to require nine months to complete. Details of the trial and contact information can be found at www.ClinicalTrials.gov.

“We are pleased to offer patients with moderate to severe psoriasis the opportunity to participate in the Phase 2 clinical trial of PH-10, which we hope will prove to be more efficacious and safer than currently existing products,†said Craig Dees, Ph.D., Chief Executive Officer of Provectus. “If the study proves to be as successful as we expect, topical PH-10 could be extremely advantageous in the treatment of psoriasis, a large underserved market in which current, highly expensive treatments may be efficacious but have a number of side effects including infections and risk of cancer.â€

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies that are safer, more effective and less invasive than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for melanoma and breast cancer, and PH-10 as a topical treatment for moderate to severe psoriasis. The Company has received orphan drug designation from the FDA for metastatic melanoma. For additional information about Provectus please visit the Company’s website at www.pvct.com or contact the Investor Relations Group via the information provided below.

FORWARD-LOOKING STATEMENTS

The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Contacts

Provectus Pharmaceuticals, Inc. R. Culpepper, CFO, 866-594-5999, Ext. 30orThe Investor Relations GroupInvestor Relations: BergorMedia:Janet Vasquez212-825-3210

Sharing Sharing These links help you add this release to websites on which you can save or share bookmarks.

Digg

del.icio.us

Newsvine

Reddit

Print this Release

Terms of Use | © Business Wire 2007